Previous Close | 0.0700 |
Open | 0.0000 |
Bid | 0.0300 x N/A |
Ask | 0.1000 x N/A |
Day's Range | 0.0000 - 0.0000 |
52 Week Range | |
Volume | |
Avg. Volume | 4,055 |
Market Cap | N/A |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
The Power Play by The Market Herald has announced the release of new interviews with Datametrex, Cloud DX, Alkaline, and GeneTether Therapeutics on their latest news.
VANCOUVER, BC / ACCESSWIRE / May 30, 2022 / The Power Play by The Market Herald has announced the release of a new interview with GeneTether Therapeutics on their latest news.The Power Play by The Market Herald provides investors with a quick snapshot of what they need to know about the company's latest press release through exclusive insights and interviews with company executives.
GeneTether Therapeutics Inc., ("GeneTether" or the "Company") (CSE: GTTX) announced today that the United States Patent and Trademark Office has granted patent #11,339,385 entitled "Modified Nucleic Acid Editing Systems for Tethering Donor DNA" related to its GeneTether platform technology. The claims cover a composition of matter for tethering a donor DNA template to a fusion protein of a nuclease and the lac repressor DNA binding domain, in particular where the donor DNA includes the lac opera